Determination of insulin resistance and its relationship with hyperandrogenemia, anti-Müllerian hormone, inhibin A, inhibin B, and insulin-like peptide-3 levels in adolescent girls with polycystic ovary syndrome
Determination of insulin resistance and its relationship with hyperandrogenemia, anti-Müllerian hormone, inhibin A, inhibin B, and insulin-like peptide-3 levels in adolescent girls with polycystic ovary syndrome
Background/aim: This study aims to investigate the association between polycystic ovary syndrome (PCOS) and obesity and insulinresistance (IR) with respect to anti-Müllerian hormone (AMH), inhibin A (INH-A), inhibin B (INH-B), and insulin-like peptide 3(INSL3) levels, all factors which may have an impact on IR.Materials and methods: In this cross sectional study, 52 adolescent girls diagnosed with PCOS [groups: nonobese (NO), n = 23;overweight/obese (OW/O), n = 29] were included. Blood samples were obtained to measure AMH, INH-B, INH-A, and INSL3 levels,together with hormonal and biochemical assessments. Oral glucose tolerance test (OGTT) was performed and the indexes of IR[homeostasis model assessment: insulin resistance (HOMA-IR) and Matsuda index] were calculated.Results: Insulin resistance was 56.5% with OGTT and 30.4% with HOMA-IR in nonobese-PCOS girls. There was a correlation betweenINH-A and HOMA-IR even when controlled for body mass index (BMI). INH-B and FAI also had correlations with HOMA-IR whichdisappeared when controlled for BMI. In regression analyses, AMH (odds ratio = [0.903, P = 0.015) and FAI (odds ratio = 1.353, P= 0.023) are found to be contributors to IR. Their effect was BMI-independent. In ROC analysis, the cutoff value for FAI was 5.93(sensitivity 71%) to define IR in PCOS girls.Conclusion: AMH and FAI may contribute to IR (defined by OGTT) in PCOS. FAI might be used as a supporting IR marker (definedby OGTT) in adolescent girls with PCOS.
___
- 1. Wiegand S, Maikowski U, Blankenstein O, Biebermann H,
Tarnow P et al. Type 2 diabetes and impaired glucose tolerance
in European children and adolescents with obesity–a problem
that is no longer restricted to minority groups. European
Journal of Endocrinology 2004; 151(2): 199-206.
- 2. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri
A. Obesity and reproductive disorders in women. Human
Reproduction Update 2003; 9: 359-372. doi: 10.1093/humupd/
dmg024
- 3. Bronstein J, Tawdekar S, Liu Y, Pawelczak M, David R et al. Age
of onset of polycystic ovarian syndrome in girls may be earlier
than previously thought. Journal of Pediatric and Adolescent
Gynecology 2011; 24: 15-20. doi: 10.1016/j.jpag.2010.06.003
- 4. Chung PW, Chan SSC, Yiu KW, Lao TTH, Chung TKH.
Menstrual disorders in a Paediatric and Adolescent
Gynaecology Clinic: patient presentations and longitudinal
outcomes. Hong Kong Medical Journal 2011; 17: 391-397.
- 5. Li HW, Anderson RA, Yeung WS, Ho PC, Ng EH. Evaluation
of serum antimullerian hormone and inhibin B concentrations
in the differential diagnosis of secondary oligoamenorrhea.
Fertility and Sterility 2011; 96: 774-779. doi: 10.1016/j.
fertnstert.2011.06.016
- 6. İliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can antiMullerian hormone predict the diagnosis of polycystic ovary
syndrome? A systematic review and meta-analysis of extracted
data. Journal of Clinical Endocrinology and Metabolism 2013;
98: 3332-3340. doi: 10.1210/jc.2013-1393
- 7. Gambineri A, Patton L, De Iasio R, Paladoro F, Pagotto U et
al. Insulin-like factor 3: a new circulating hormone related to
luteinizing hormone-dependent ovarian hyperandrogenism
in the polycystic ovary syndrome. Journal of Clinical
Endocrinology and Metabolism 2007; 92: 2066-2073. doi:
10.1210/jc.2006-1678
- 8. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B
et al. Serum levels of inhibins are differentially altered in patients
with polycystic ovary syndrome: effects of being overweight and
relevance to hyperandrogenism. Fertility and Sterility 2000; 73:
972-977. doi: 10.1016/S0015-0282(00)00421-0
- 9. Segal S, Elmadjian M, Takeshiqe T, Karp S, Mercado R et al.
Serum inhibin A concentration in women with polycystic
ovarian syndrome and the correlation to ethnicity, androgens
and insulin resistance. Reproductive BioMedicine Online
2010; 20: 675-680. doi: 10.1016/j.rbmo.2010.02.006
- 10. Yetim A, Yetim Ç, Baş F, Erol OB, Çığ G et al. Anti-Müllerian
hormone and inhibin A, but not inhibin B or insulin-like
peptide-3, may be used as surrogates in the diagnosis of
polycystic ovary syndrome in adolescents: preliminary results.
Journal of Clinical Research in Pediatric Endocrinology 2016;
8: 288-297. doi: 10.4274/jcrpe.3253
- 11. Cassar S, Teede HJ, Moran LJ, Joham AE, Harrison CL et al.
Polycystic ovary syndrome and anti-Müllerian hormone: role
of insulin resistance, androgens, obesity and gonadotrophins.
Clinical Endocrinology 2014; 81: 899-906. doi: 10.1111/
cen.12557
- 12. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum
antiMullerian hormone throughout the human menstrual
cycle. Human Reproduction 2006; 21: 3103-3107. doi: 10.1093/
humrep/del291
- 13. Carmina E, Orio F, Palomba S, Longo RA, Lombardi G et al.
Ovarian size and blood flow in women with polycystic ovary
syndrome and their correlations with endocrine parameters.
Fertility and Sterility 2005; 84: 413-419. doi: 10.1016/j.
fertnstert.2004.12.061
- 14. Tokmak A, Kokanali D, Timur H, Kuntay Kokanali M, Yılmaz
N. Association between anti-Mullerian hormone and insulin
resistance in non-obese adolescent females with polycystic
ovary syndrome. Gynecological Endocrinology 2016; 32: 926-
930. doi: 10.1080/09513590.2016.1193140
- 15. Chun S. 1-h Postprandial glucose level is related to the serum
anti-Müllerian hormone level in women with polycystic ovary
syndrome. Gynecological Endocrinology 2015; 31: 815-818.
doi: 10.3109/09513590.2015.1056143
- 16. Fonseca HP, Brondi RS, Piovesan FX, Miklos TG, Aldrighi JM.
Anti-Mullerian hormone and insulin resistance in polycystic
ovary syndrome. Gynecological Endocrinology 2014; 30: 667-
670. doi: 10.3109/09513590.2014.920004
- 17. Kim JY, Tfayli H, Michaliszyn SF, Lee S, Nasr A et al. AntiMüllerian hormone in obese adolescent girls with polycystic
ovary syndrome. Journal of Adolescent Health 2017; 60: 333-
339. doi: 10.1016/j.jadohealth.2016.10.015
- 18. Cengiz H, Ekin M, Dagdeviren H, Yıldız Ş, Kaya C
et al. Comparison of serum anti-Müllerian hormone
levels in normal weight and overweight-obese adolescent
patients with polycystic ovary syndrome. European Journal of
Obstetrics & Gynecology and Reproductive Biology 2014; 180:
46-50. doi: 10.1016/j.ejogrb.2014.06.018
- 19. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ
et al. Insulin resistance in polycystic ovary syndrome:
a systematic review and meta-analysis of euglycaemichyperinsulinaemic clamp studies. Human Reproduction 2016;
31: 2619-2631. doi: 10.1093/humrep/dew243
- 20. Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic
ovary syndrome: impact on oocyte maturation and embryo
developmental competence. Human Reproduction Update
2011; 17: 17–33. doi: 10.1093/humupd/dmq032
- 21. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante
G et al. Genetic, hormonal and metabolic aspects of PCOS:
an update. Reproductive Biology and Endocrinology 2016; 14:
38. doi: 10.1186/s12958-016-0173-x
- 22. Cortet-Rudelli C, Pigny P, Decanter C, Leroy M, MaunouryLefebvre C et al. Obesity and serum luteinizing hormone level
have an independent and opposite effect on the serum inhibin
B level in patients with polycystic ovary syndrome. Fertility and
Sterility 2002; 77: 281-287. doi: 10.1016/S0015-0282(01)02968-5
- 23. Welt CK, Taylor AE, Martin KA, Hall JE. Serum inhibin B
in polycystic ovary syndrome. Regulation by insulin and
luteinizing hormone. Journal of Clinical Endocrinology and
Metabolism 2002; 87: 5559–5565. doi: 10.1210/jc.2002-020546
- 24. Ferriman D, Gallwey JD. Clinical assessment of body hair
growth in women. Journal of Clinical Endocrinology and
Metabolism 1961; 21: 1440-1447. doi: 10.1210/jcem-21-11-1440
- 25. Neyzi O, Bundak R, Gökçay G, Furman A, Darendeliler F et
al. Reference values for weight, height, head circumference,
and body mass index in Turkish children. Journal of Clinical
Research in Pediatric Endocrinology 2015; 7: 280-293. doi:
10.4274/jcrpe.2183
- 26. Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu MM, Akın MA, Çoban D
et al. Body weight, length and head circumference at birth in
a cohort of Turkish newborns. Journal of Clinical Research
in Pediatric Endocrinology 2012; 4: 132-139. doi: 10.4274/
jcrpe.693
- 27. Unalan D, Senol V, Bayat M, Mazicioğlu MM, Ozturk A et al.
Change in waist circumference over 3 years in Turkish children
and adolescents. Annals of Human Biology 2013; 40: 419-
425. doi: 10.3109/03014460.2013.791720
- 28. National High Blood Pressure Education Program Working
Group on High Blood Pressure in Children and Adolescents.
The fourth report on the diagnosis, evaluation, and treatment
of high blood pressure in children and adolescents. Pediatrics
2004; 114 (2 Suppl 4th Report): 555-576.
- 29. Matthews D, Hosker J, Rudenski A, Naylor BA, Treacher DF et
al. Homeostasis model assessment: insulin resistance and β-cell
function from fasting plasma glucose and insulin concentrations
in man. Diabetologia 1985; 28: 412-419.
- 30. Matsuda M, De Fronzo RA. Insulin sensitivity indices obtained
from oral glucose tolerance testing: comparison with the
euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
doi: 10.2337/diacare.22.9.1462
- 31. American Diabetes Association. Standards of medical care
in diabetes. Diabetes Care 2011; 34:S11-S61. doi: 10.2337/
dc11-S011
- 32. Reaven GM, Brand JR, Chen YD, Mathur AK, Goldfine I.
Insulin resistance and insulin secretion are determinants of
oral glucose tolerance in normal individuals. Diabetes 1993;
42:1324-1332. doi: 10.2337/diab.42.9.1324
- 33. Zannolli R, Rebeggiani A, Chiarelli F, Morgese G.
Hyperinsulinism a marker in obese children. American Journal
of Diseases of Children 1993; 147: 837-841.
- 34. Flannery CA, Rackow B, Cong X, Duran E, Selen
DJ et al. Polycystic ovary syndrome in adolescence:
impaired glucose tolerance occurs across the spectrum of
BMI. Pediatr Diabetes 2013; 14: 42-49. doi: 10.1111/j.1399-
5448.2012.00902.x
- 35. Coles N, Bremer K, Kives S, Zhao X, Hamilton J. Utility of the
oral glucose tolerance test to assess glucose abnormalities in
adolescents with polycystic ovary syndrome. Journal of Pediatric
and Adolescent Gynecology 2016; 29: 48-52. doi: 10.1016/j.
jpag.2015.06.004
- 36. Hart R, Doherty DA, Mori T, Huang RC, Norman RJ et al.
Extent of metabolic risk in adolescent girls with features of
polycystic ovary syndrome. Fertility and Sterility 2011; 95:
2347-2353. doi: 10.1016/j.fertnstert.2011.03.001
- 37. Reyes-Muñoz E, Ortega-González C, Matínez-Cruz N, ArceSánchez L, Estrada-Gutierrez G et al. Association of obesity
and overweight with the prevalence of insulin resistance,
pre-diabetes and clinical-biochemical characteristics
among infertile Mexican women with polycystic ovary
syndrome: a cross-sectional study. BMJ Open 2016; 6:e012107.
doi: 10.1136/bmjopen-2016-012107
- 38. Cui Y, Shi Y, Cui L, Han T, Gao X et al. Agespecific serum antimüllerian hormone levels in women with
and without polycystic ovary syndrome. Fertility and Sterility
2014; 102: 230-236. doi: 10.1016/j.fertnstert.2014.03.032
- 39. Cui L, Qin Y, Gao X, Lu J, Geng L et al. Anti-Müllerian
hormone: correlation with age and androgenic and
metabolic factors in women from birth to postmenopause.
Fertility and Sterility 2016; 105: 481-485. doi: 10.1016/j.
fertnstert.2015.10.017
- 40. Skalba P, Cygal A, Madej P, Dąbkowska-Huć A,
Sikora J, Martirosian G et al. Is the plasma antiMüllerian hormone (AMH) level associated with body
weight and metabolic, and hormonal
disturbances in women with and without polycystic ovary
syndrome? European Journal of Obstetrics & Gynecology
and Reproductive Biology 2011; 158: 254-259. doi: 10.1016/j.
ejogrb.2011.06.006
- 41. Feldman RA, O’Neill K, Butts SF, Dokras A. Antimüllerian
hormone levels and cardiometabolic risk in young women
with polycystic ovary syndrome. Fertility and Sterility 2016;
107: 276-281. doi: 10.1016/j.fertnstert.2016.10.009
- 42. Garg D, Tal R. The role of AMH in the pathophysiology of
polycystic ovarian syndrome. Reproductive BioMedicine
Online 2016; 33: 15-28. doi: 10.1016/j.rbmo.2016.04.007